Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 35 * 三生 制药 3SBIO INC . ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 1530 ) ( Convertible Bonds Code : 40285 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 FINANCIAL HIGHLIGHTS * Notes : 1 2 Revenue increased by RMB412.0 million or 15.3 % to RMB3,107.1 million , as compared to the six months ended 30 June 2020 . Gross profit increased by RMB370.1 million or 16.7 % to RMB2,587.1 million , as compared to the six months ended 30 June 2020. The gross profit margin increased to 83.3 % from 82.3 % for the six months ended 30 June 2020 . Research and development costs increased by RMB90.5 million or 35.6 % to RMB344.9 million , accounting for 11.1 % of revenue . Net profit attributable to owners of the parent increased by RMB196.4 million or 28.0 % to RMB898.9 million , as compared to the six months ended 30 June 2020. Normalized net profit attributable to owners of the parent ' increased by RMB180.8 million or 24.1 % to RMB929.8 million , as compared to the six months ended 30 June 2020 . EBITDA increased by RMB174.5 million or 17.4 % to RMB1,177.4 million , as compared to the six months ended 30 June 2020. Normalized EBITDA² increased by RMB128.2 million or 12.2 % to RMB1,177.6 million , as compared to the six months ended 30 June 2020 . Total comprehensive income increased by RMB73.0 million or 7.8 % to RMB1,014.4 million , as compared to the six months ended 30 June 2020 . All numbers in the “ Financial Highlights " section are subject to rounding adjustments and therefore approximate numbers only . The normalized net profit attributable to owners of the parent is defined as the profit for the period excluding , as applicable : ( a ) the interest expenses incurred in relation to the issuance of the Euro - denominated zero - coupon convertible bonds ( " Bonds " ) in an aggregate principal amount of EUR300,000,000 due 2022 ( the “ 2022 Bonds " ) and the Bonds in an aggregate principal amount of EUR320,000,000 due 2025 ( the “ 2025 Bonds " ) ; ( b ) the expenses associated with the share options and awarded shares granted in February 2017 and March 2020 ; ( c ) the expenses associated with the share options under an employee share ownership plan ( the “ ESOP ” ) of Sunshine Guojian Pharmaceutical ( Shanghai ) Co. , Ltd. ( " Sunshine Guojian ” ) , an indirect non - wholly owned subsidiary of 3SBio Inc. ( “ 3SBio " or the " Company " ) ; and ( d ) gain on deemed disposal of investment in associates . The normalized EBITDA is defined as the EBITDA for the period excluding the same items as listed in Note 1 above .